Long-term response to crizotinib in a 17-year-old boy with treatment-naive ALK-positive non-small-cell lung cancer

被引：1

作者：

Megaro, Giacomina ^{[1
]}

Miele, Evelina ^{[1
]}

Spinelli, Gian Paolo ^{[2
]}

Alessi, Iside ^{[1
]}

Del Baldo, Giada ^{[1
]}

Cozza, Raffaele ^{[1
]}

Russo, Ida ^{[1
]}

De Pasquale, Maria Debora ^{[1
]}

Cefalo, Maria Giuseppina ^{[1
]}

Toma, Paolo ^{[3
]}

Carai, Andrea ^{[4
]}

Di Ruscio, Valentina ^{[1
]}

De Ioris, Maria Antonietta ^{[1
]}

Mastronuzzi, Angela ^{[1
]}

机构：

[1] Bambino Gesu Pediat Hosp, IRCCS, Dept Hematol Oncol Cell & Gene Therapy, Rome, Italy

[2] Sapienza Univ Rome Aprilia, UOC Oncol Univ, ASL Latina Distretto Aprilia, Latina, Italy

[3] Bambino Gesu Pediat Hosp, IRCCS, Dept Imaging, Rome, Italy

[4] Bambino Gesu Pediat Hosp, IRCCS, Dept Neurosci, Neurosurg Unit, Rome, Italy

来源：

CANCER REPORTS | 2022年 / 5卷 / 03期

关键词：

adenocarcinoma; adolescence; ALK; crizotinib; lung; PULMONARY TUMORS; YOUNG; ADENOCARCINOMA; ALECTINIB;

D O I：

10.1002/cnr2.1483

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80-90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3-7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case We present a case of a 17-year-old male with metastatic treatment-naive ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion Crizotinib can be extremely effective in adolescents with treatment-naive ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.

引用

页数：4

共 31 条

[1] Epidemiology of lung cancer: Looking to the future [J].

Alberg, AJ ;

Brock, MV ;

Samet, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3175-3185

[2]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[3] Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases [J].

Costa, Daniel B. ;

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Solomon, Benjamin J. ;

Riely, Gregory J. ;

Ahn, Myung-Ju ;

Zhou, Caicun ;

Shreeve, S. Martin ;

Selaru, Paulina ;

Polli, Anna ;

Schnell, Patrick ;

Wilner, Keith D. ;

Wiltshire, Robin ;

Camidge, D. Ross ;

Crino, Lucio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1881-1888

[4] The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis [J].

Fan, Junsheng ;

Fong, Tszhei ;

Xia, Zengfei ;

Zhang, Jian ;

Luo, Peng .

CANCER MEDICINE, 2018, 7 (10) :4993-5005

[5] The efficacy and safety of alectinib in the treatment of ALK plus NSCLC: a systematic review and meta-analysis [J].

Fan, Junsheng ;

Xia, Zengfei ;

Zhang, Xiaoli ;

Chen, Yuqing ;

Qian, Ruolan ;

Liu, Sihan ;

You, Danming ;

Zhang, Jian ;

Luo, Peng .

ONCOTARGETS AND THERAPY, 2018, 11 :1105-1115

[6]

Forman D, 2014, IARC Scientific Publications, VX

[7] The role of the ALK receptor in cancer biology [J].

Hallberg, B. ;

Palmer, R. H. .

ANNALS OF ONCOLOGY, 2016, 27 :4-15

[8] Lung cancer: current therapies and new targeted treatments [J].

Hirsch, Fred R. ;

Scagliotti, Giorgio V. ;

Mulshine, James L. ;

Kwon, Regina ;

Curran, Walter J. ;

Wu, Yi-Long ;

Paz-Ares, Luis .

LANCET, 2017, 389 (10066) :299-311

[9] Lymphoma in Adolescents and Young Adults [J].

Hochberg, Jessica ;

Cairo, Mitchell S. .

CANCER JOURNAL, 2018, 24 (06) :285-300

[10]

Hoffmann-La R., ALECENSA ALECTINIB H

← 1 2 3 4 →